| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 |
|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities | ||||||||
Net loss | ||||||||
-93,243 | -85,372 | -75,285 | -64,701 | -55,006 | -43,538 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | ||||||||
1,500 | 1,500 | 1,100 | 800 | 539 | 200 | 0 | 0 | 0 |
Stock-based compensation | ||||||||
20,419 | 15,764 | 12,438 | 9,457 | 6,790 | 4,570 | 0 | 0 | 0 |
Net amortization of premiums and discounts on marketable securities | ||||||||
1,641 | 2,664 | 2,759 | 2,551 | 2,112 | 1,310 | 0 | 0 | 0 |
Noncash lease expense | ||||||||
272 | 275 | 207 | 142 | 73 | 0 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||
Prepaid expenses and other current assets | ||||||||
970 | -463 | -1,509 | -2,070 | -1,604 | 1,489 | 0 | 0 | 0 |
Other long-term assets | ||||||||
- | - | - | - | - | -313 | 0 | 0 | 0 |
Accounts payable | ||||||||
5,385 | 3,571 | 892 | 1,597 | 1,347 | 76 | 0 | 0 | 0 |
Accrued expenses and other current liabilities | ||||||||
727 | 4,077 | 5,078 | 3,516 | 3,244 | 2,063 | 0 | 0 | 0 |
Other long-term liabilities | ||||||||
-276 | -70 | 351 | 638 | 911 | 705 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||
-68,321 | -63,000 | -56,549 | -48,701 | -42,388 | -38,450 | 0 | 0 | 0 |
Cash flows from investing activities | ||||||||
Purchases of marketable securities | ||||||||
485,994 | 541,701 | 336,558 | 307,839 | 307,360 | 236,601 | 0 | 0 | 0 |
Proceeds from maturities of marketable securities | ||||||||
280,000 | 230,500 | 272,500 | 238,500 | 173,500 | 92,500 | 0 | 0 | 0 |
Purchases of property and equipment | ||||||||
697 | 770 | 3,381 | 5,914 | 7,050 | 6,946 | 0 | 0 | 0 |
Net cash provided by investing activities | ||||||||
-206,691 | -311,971 | -67,439 | -75,253 | -140,910 | -151,047 | 0 | 0 | 0 |
Cash flows from financing activities | ||||||||
Proceeds from issuance of common stock, net of issuance costs | ||||||||
- | - | - | - | - | 138,357 | 0 | 0 | 0 |
Proceeds from exercise of stock options | ||||||||
- | - | - | - | - | - | - | - | 0 |
Proceeds from exercise of stock options | ||||||||
2,113 | 2,448 | 0 | 0 | 0 | - | - | - | - |
Proceeds from issuance of common stock under the 2018 ESPP | ||||||||
0 | - | - | - | 0 | - | - | - | - |
Payments for deferred financing costs | ||||||||
- | - | - | - | - | - | - | 0 | 0 |
Net cash provided by financing activities | ||||||||
380,989 | 381,163 | 381,159 | 141,118 | 140,162 | 138,752 | 0 | 0 | 0 |
Net increase (decrease) in cash, cash equivalents and restricted cash | ||||||||
105,951 | 6,180 | 257,170 | 17,162 | -43,136 | -50,745 | 0 | 0 | 0 |
Noncash investing and financing items: | ||||||||
Right-of-use assets obtained in exchange for lease obligations | ||||||||
0 | 6,050 | 6,050 | 6,050 | 6,050 | 0 | 0 | 0 | 0 |
Property and equipment purchased in accounts payable | ||||||||
-412 | 0 | -1,402 | 299 | 732 | 313 | 0 | 0 | 0 |
Deferred initial public offering costs in accounts payable | ||||||||
- | - | - | - | - | - | - | - | 0 |
Vesting of restricted common stock subject to repurchase | ||||||||
14 | 20 | 24 | 24 | 24 | 24 | 0 | 0 | 0 |